Cell therapy

#Antibodies #Biologics #Biologics / Biotechnology #Cell therapy

IONTAs and FairJourney antibody agreement with Quell Therapeutics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Cell therapy #Cold chain

Cytiva and Brooks Life Sciences enhance automation in cold chain solutions

Cytiva and Brooks Life Sciences, a division of Brooks Automation, are working together to expand Cytiva’s Chronicle software capabilities to integrate Brooks Life Sciences BioStore III automated storage platform. This has been purpose built to handle a range of high value materials between the temperatures of -20°C and -190°C in… Read More

#News

#Cell therapy #Immunology

Lonza releases cryopreserved leukopaks for immunology and cell therapy research

Lonza has launched fully customisable, cryopreserved Leukopaks. The frozen Leukopaks will enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks. Being suitable for long-term storage in research labs, the cryopreserved Leukopaks will also allow immediate access to viable cells for greater convenience… Read More

#News

#Biologics #Cell therapy

Solentim new standards in productivity with antibodies workflow solutions

Solentim, expert in cell therapy workflows enabling the creation, isolation and characterisation of high value cells, has launched two solutions to enhance the development of therapeutic antibodies. Icon is a benchtop system for the rapid stratification of high productivity clones and Studius is a proprietary software platform that delivers data… Read More

#News

#Biologics #Cell therapy #CRISPR #Gene therapy #Immuno-oncology

Cognate BioServices announces major US and Europe expansion

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new… Read More

#News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

Funding to UK cell and gene therapy training centre to strengthen skills pipeline

The Cell and Gene Therapy Catapult (CGT Catapult) and Hertfordshire Local Enterprise Partnership (LEP) in the UK have announced that a new cell and gene therapy integration laboratory at the CGT Catapult facility in Stevenage will be part-funded by the government’s Getting Building Fund. The new laboratory will be exclusively… Read More

#Editor's Choice #News

#Biologics / Biotechnology #Biomanufacturing #Cell therapy #Drug development

Cedars-Sinai biomanufacturing centre spurs cell therapies to help develop new drugs

Cedars-Sinai has launched a centre to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries. Biologic drugs are produced from living organisms or contain components of living… Read More

#Editor's Choice #News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Cell therapy #Gene therapy

Digitalising cell and gene therapies manufacturing: a case study

Lonza will be hosting a free webinar to discuss its innovative approach to digitalising the company’s cell and gene therapy manufacturing operations through the implementation of the MODA-ESTM Platform. It will take place on 17 November. In the webinar, Lonza will also outline future plans for utilising the platform to… Read More

#News

#Cell therapy #Therapeutics

Catalent to acquire Bone Therapeutics’ cell therapy facility for €12 million

Bone Therapeutics, the cell therapy company and Catalent Pharma Solutions, provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies have announced the signing of share purchase and supply agreements. The agreements will streamline and economise the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic… Read More

#News

#Cell therapy #Gene therapy

Bayer acquires AskBio to broaden innovation in cell and gene therapy

Bayer has acquired Asklepios BioPharmaceutical (AskBio) a US-headquartered biopharmaceutical company specialising in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases. Bayer will own full… Read More

#News #Trending News

#Cell therapy

New platform identifies epigenetic switches driving cell identity and cell maintenance

Mogrify’s EpiMOGRIFY platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion. EpiMOGRIFY is an extension of the company’s proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells… Read More

#News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

High potential opportunity zone named for cell and gene therapy

The UK Department for International Trade (DIT) has classified Stevenage in the UK, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected… Read More

#News

#Cell therapy #Gene therapy

Analytical thinking: a focus on cell & gene therapeutic analysis

Absorption Systems works collaboratively with biotech and pharma companies. Dealing with their future therapeutics, the company’s analytical research services help customers streamline and simplify the approval process. Lu Rahman found out more from CEO Patrick Dentinger. LR: Describe Absorption Systems’ analytical testing expertise in relation to cell and gene therapy… Read More

#Exclusive Content

#Bioproduction #Cell therapy #CPhI #Gene therapy

Report spots cell & gene therapy capacity shortages in the USA

CPhI Annual Report 2020 highlights cell and gene therapy capacity shortages in the USA and 10+ mAb approvals in China. Continuous Bioprocessing growing quickly, but from a low base, with virtually all manufacturers now using at least some single use technologies. CPhI Annual Report – launched ahead of the… Read More

#News

#Cell therapy #Gene therapy #ISCT

ISCT in focus

The International Society for Cell & Gene Therapy (ISCT) has a vision - to translate cell and gene research into safe and effective therapies to improve patients’ lives worldwide. Queenie Jang, CEO, explains…. Established in 1992, the ISCT  is a global society of over 2300 clinicians, regulators, researchers, technologists and industry… Read More

#Exclusive Content